Loading...
XNASIMAB
Market cap33mUSD
Dec 24, Last price  
0.92USD
1D
-5.44%
1Q
-14.02%
IPO
-93.33%
Name

I-Mab

Chart & Performance

D1W1MN
XNAS:IMAB chart
P/E
—
P/S
20.21
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
96.53%
Rev. gr., 5y
-12.46%
Revenues
28m
P
11,556,00053,781,00030,000,0001,542,668,00088,026,000-221,563,00027,644,000
Net income
-1.47b
L-41.54%
-298,240,000-402,833,000-1,485,001,000470,915,000-2,331,541,000-2,507,317,000-1,465,694,000
CFO
-1.30b
L+18.33%
-252,157,000-280,705,000-867,982,000433,558,000-973,093,000-1,102,805,000-1,304,950,000
Earnings
Mar 12, 2025

Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
URL
https://www.i-mabbiopharma.com/
IPO date
Jan 17, 2020
Employees
378
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
27,644
-112.48%
(221,563)
-351.70%
88,026
-94.29%
Cost of revenue
178,267
1,747,904
2,159,333
Unusual Expense (Income)
NOPBT
(150,623)
(1,969,467)
(2,071,307)
NOPBT Margin
888.90%
Operating Taxes
697
3,154
Tax Rate
NOPAT
(150,623)
(1,970,164)
(2,074,461)
Net income
(1,465,694)
-41.54%
(2,507,317)
7.54%
(2,331,541)
-595.11%
Dividends
Dividend yield
Proceeds from repurchase of equity
(21,249)
BB yield
14.17%
Debt
Debt current
7,316
42,917
30,669
Long-term debt
9,605
88,099
194,241
Deferred revenue
267,878
224,000
Other long-term liabilities
479,738
105,650
14,934
Net debt
(2,274,312)
(3,349,268)
(4,432,228)
Cash flow
Cash from operating activities
(1,304,950)
(1,102,805)
(973,093)
CAPEX
(11,351)
(45,830)
(29,932)
Cash from investing activities
102,515
458,382
(727,206)
Cash from financing activities
7,572
42,357
593,924
FCF
(38,353)
(1,579,442)
(2,548,880)
Balance
Cash
2,289,529
3,449,434
4,276,796
Long term investments
1,704
30,850
380,342
Excess cash
2,289,851
3,491,362
4,652,737
Stockholders' equity
(8,285,745)
(6,549,800)
(4,541,217)
Invested Capital
10,494,214
10,006,640
9,480,402
ROIC
ROCE
EV
Common stock shares outstanding
83,228
82,516
75,960
Price
0.83
-54.55%
1.82
-91.18%
20.60
0.51%
Market cap
68,753
-54.15%
149,964
-90.42%
1,565,098
11.68%
EV
(2,205,559)
(3,199,304)
(2,867,130)
EBITDA
(143,187)
(1,905,651)
(2,037,171)
EV/EBITDA
15.40
1.68
1.41
Interest
102
Interest/NOPBT